12–month negative control outcomes in patients with obesity and TUD (no T2D)
(comparison between propensity–score matched cohorts: semaglutide vs smoking cessation medications)

Outcome	Semaglutide cohort # of cases (overall risk)	Smoking cessation medications cohort # of cases (overall risk)		HR (95% CI)
Semaglutide vs Nicotine replacement therapy (n=1,131/cohort)				
Positive test for SARS–CoV2	51 (4.5%)	45 (4.0%)		1.13 (0.76–1.69)
Nail disorders	14 (1.2%)	16 (1.4%)		0.87 (0.42–1.77)
Injuries to the ankle and foot	41 (3.6%)	38 (3.4%)		1.07 (0.69–1.66)
Injuries to the shoulder and upper arm	27 (2.4%)	28 (2.5%)		0.96 (0.56–1.63)
Semaglutide vs Bupropion/Varenicline (n=1,173/cohort)				
Positive test for SARS–CoV2	51 (4.3%)	54 (4.6%)		0.95 (0.65–1.40)
Nail disorders	17 (1.4%)	<10 (<0.9%)		1.71 (0.78–3.74)
Injuries to the ankle and foot	41 (3.5%)	45 (3.8%)		0.91 (0.60–1.39)
Injuries to the shoulder and upper arm	28 (2.4%)	34 (2.9%)		0.83 (0.50–1.37)

0.10 0.30 0.90 3.00 9.00
Hazard Ratio (HR)